Yeung outlined a timeline of growth since launch. He said IM8 began selling online in December 2024 and generated $581,000 in revenue in its first month. In January, the company held a public launch in New York, and Beckham appeared on the TODAY show to promote the product, which Yeung said drove PR and media exposure.On athlete adoption, Yeung cited Aryna Sabalenka, the world’s No. 1 women’s tennis player, saying she took the product for three months before contacting the company. He also said IM8 recently ...

Prenetics Global (NasdaqGM:PRE) FY Conference March 23, 2026 03:00 PM ET Company ParticipantsDanny Yeung - CEO and Co-founderJason Wersland - FounderNate Raabe - Managing PartnerShadi Bakour - Co-founder and CEOShahab Elmi - Founder and CEOConference Call ParticipantsNone - AnalystNone - AnalystNate RaabeAll right, we're missing a panelist here. I think he's talking with Mr. Johnson out there, so he may join us later. We're gonna go ahead and get started here. There'll be people trickling in. My name is Nat ...

Prenetics Global (NasdaqGM:PRE) FY Conference March 23, 2026 11:30 AM ET Company ParticipantsDanny Yeung - Co-Founder and CEOConference Call ParticipantsGeorge Kelly - Managing Director and Senior Research AnalystNone - AnalystNone - AnalystNone - AnalystGeorge KellyHi, everybody. I'm George Kelly with Roth. Excited to have Danny Yeung, who's the Co-Founder and CEO of Prenetics, with me today. We don't have a ton of time, just like 25 minutes. I'll stop every once in a while and take questions if there are ...

Prenetics Global logo Prenetics Global (NASDAQ:PRE) CEO and co-founder Danny Yeung told investors the company delivered what he described as a “breakout growth story” in 2025, driven by the rapid expansion of its IM8 direct-to-consumer supplements business and a broader strategic shift to focus on that brand. 2025 performance and IM8 ramp Yeung said Prenetics generated approximately $92 million in full-year 2025 revenue, inclusive of multiple business units. He attributed the results largely to IM8, whi ...

Prenetics Global Conference Call Summary Company Overview - **Company**: Prenetics Global (NasdaqGM:PRE) - **Key Product**: IM8, a health supplement brand launched in December 2024 - **2025 Revenue**: Approximately $92 million, with IM8 contributing $120 million ARR in its first year of operations [1][2] Financial Performance - **2025 Full Year Revenue**: $92 million, with IM8 generating $120 million ARR [1][2] - **Gross Margins**: 63% for IM8 [2] - **Liquidity**: Approximately $160 million in liquid assets, zero debt [2] - **Divestments**: Sold non-core assets including ACT for $72 million, Europa for $13 million, and Insighta to Tencent for $70 million [2][3] Growth Strategy - **Roadmap to Profitability**: Expected by Q4 2027 [2] - **Market Expansion**: IM8 operates in 31 countries, with the U.S. representing 40% of revenue [3][4] - **Customer Base**: Target demographic is ages 30-60, top 10% of household incomes [20][21] - **Marketing Channels**: Currently focused on Meta and Google, with plans to diversify into TikTok, YouTube, and AppLovin [15][24] Product Development - **New Offerings**: Introduction of a three-month subscription option, increasing average order value to approximately $233 [8][9] - **Product Formulation**: Daily Ultimate Essentials and Daily Ultimate Longevity targeting health and aging [12][13] - **Clinical Trials**: Three new clinical trials planned, including collaboration with Mayo Clinic [27] Customer Acquisition and Retention - **Customer Acquisition Cost (CAC)**: $130, with a 24-month Lifetime Value (LTV) of approximately $480 [6] - **Subscription Rate**: 80% of new customers opt for subscriptions, providing predictable revenue [9] Marketing and Brand Ambassadors - **Ambassadors**: Includes David Beckham, Aryna Sabalenka, and Ollie Bearman, who are also shareholders [10][11] - **Social Media Impact**: A viral video reached 233 million views, enhancing brand visibility [11] Future Outlook - **Revenue Guidance for 2026**: Projected revenue of $180 million-$200 million, representing 300% year-over-year growth [17] - **Market Localization**: Plans to enter new markets with tailored marketing strategies [16] - **Long-term Vision**: Aiming for a billion-dollar valuation, with strong brand recognition and customer loyalty [18] Additional Insights - **Bitcoin Holdings**: Currently holding 510 Bitcoins, treated as a treasury asset [3][30] - **Share Buyback Program**: Announced a $40 million share buyback, with $2.75 million already executed by management [32] Conclusion - Prenetics has successfully transformed into a rapidly growing consumer brand, leveraging strong product offerings, strategic marketing, and a clear path to profitability. The company is well-positioned for future growth with significant cash reserves and a focus on expanding its market presence.

Core Insights - Prenetics Global Limited (NASDAQ:PRE) reported a remarkable 480% year-over-year revenue increase to $92.4 million for 2025, driven by the success of its IM8 brand, which achieved an annual recurring revenue (ARR) of $120 million within its first year [1][7] - The company has undergone a strategic transformation by divesting non-core assets, including a $70 million cash sale of its stake in Insighta to Tencent, resulting in approximately $171 million in adjusted liquidity and zero debt [2] - Looking ahead to 2026, Prenetics reaffirmed its revenue guidance for IM8 at $180 to $200 million, with an aim for an ARR of up to $300 million by year-end, supported by a shift towards quarterly subscription models [3] Financial Performance - Q4 revenue reached $36.6 million, reflecting a 55% increase over the previous quarter, indicating strong market traction for the IM8 brand co-founded by David Beckham [1] - The average order value has increased to approximately $233 in early 2026, contributing to the anticipated revenue growth [3] Business Strategy - Prenetics is focusing on becoming a pure-play leader in the consumer health and nutrition sector, having ceased all cryptocurrency purchases while maintaining a permanent holding of 510 BTC [2] - The company operates in the health sciences sector, offering health and wellness products under the IM8 brand and providing fulfillment and distribution services for sports nutrition products under the Europa brand [4]

Market Insights - Saira Malik, Nuveen Chief Investment Officer, identified four primary themes driving market volatility in the upcoming year: trade, AI, the Middle East situation, and future actions of central banks [1] - Malik noted a significant shift in the tech sector from semiconductors to software, highlighting that software was previously under-owned in portfolios by approximately 100 to 150 basis points, leading to increased investor interest [1] Historical Context - Malik provided a historical perspective indicating that midterm election years typically experience high intra-year volatility, with markets declining an average of 18% at some point during such years, suggesting potential volatility ahead [2] Federal Reserve Expectations - In midterm years where the Fed is not raising rates and the economy is growing, major downside outcomes are often avoided; Malik expects the Fed to likely cut rates twice in the second half of the year [3] - Malik clarified her view on Kevin Warsh, seeing him as a productivity bull rather than an inflation hawk, suggesting that accelerating productivity can keep inflation in check while a weakening employment market allows for rate cuts [3] Micro-Cap Stocks Overview - A list of 12 promising micro-cap stocks was highlighted, with a focus on those trading between $50 million and $300 million and having an average upside potential of at least 30% [4][6] - The methodology for selecting these stocks involved identifying companies with recent noteworthy developments likely to impact investor sentiment, which are also favored by analysts and elite hedge funds [6][7] Company Highlights - Arqit Quantum Inc. (NASDAQ:ARQQ) partnered with 6WIND to launch integrated, quantum-safe VPN services, addressing the growing threat of quantum computing to traditional public-key infrastructure [8][9] - Prenetics Global Limited (NASDAQ:PRE) reported a 480% year-over-year revenue surge to $92.4 million, driven by its health and longevity brand, IM8, which reached an ARR of $120 million within a year of launch [12][13] - Prenetics completed a strategic transformation by divesting non-core assets, including a $70 million cash sale to Tencent, resulting in approximately $171 million in adjusted liquidity and zero debt [13] - Looking ahead, Prenetics reaffirmed its revenue guidance for IM8 at $180 to $200 million, aiming for an ARR of up to $300 million by year-end, driven by a shift toward quarterly subscription models [14]

Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4][14] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit in Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13][14] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the clear driver of revenue, generating $60.1 million for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate in its first year, with Q4 revenue of $27.4 million [4][9] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [10] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those markets [47] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets to focus on becoming a pure-play consumer health leader [5][6] - The balance sheet is strong, with approximately $171 million in total liquidity and zero debt, allowing for investment in IM8's global expansion [8] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, with a revenue guidance of $180 million-$200 million for 2026, representing nearly 300% year-over-year growth [15] - The company is excited about launching two new products in Q4 2026, which are expected to enter large total addressable markets [16][26] Other Important Information - The company ceased all Bitcoin purchases as of December 4, 2025, and will not engage in any future Bitcoin or crypto purchases [8] - Research coverage has been initiated by Roth Capital Partners and Sidoti & Company, both with buy ratings and price targets of $36 and $30 respectively [12] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][21][22] Question: Timing and nature of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements, targeting large total addressable markets [26] Question: Revenue guidance and trends - Management confirmed continued momentum in January and stated that new products are not included in the revenue guidance of $180 million-$200 million [27][28] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, rolling out numerous ads weekly and optimizing based on performance [34][35][36] Question: Strategic M&A strategy - The focus is on organic growth, but the company remains open to strategic M&A opportunities if they align with business goals [39] Question: Revenue growth sources - The majority of growth is expected from acquiring new customers, with significant potential in the US market [45][46]

Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for the full year was $48.9 million, an approximately 428% increase, with a consolidated gross margin of 59% in Q4 [13][14] - Adjusted EBITDA loss for the fourth quarter improved by 70.4% year-over-year to $2.3 million, while the full-year adjusted EBITDA loss improved by 27% to $13 million [13][14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of growth, generating $60.1 million in revenue for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue for IM8 at $27.4 million [4][10] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the U.S., with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those regions [48] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets, including the sale of ACT Genomics for $72 million and a 35% stake in Insighta to Tencent for $70 million [5][7] - The focus is on building IM8 into a global consumer health powerhouse, with plans to launch two new products in the health and performance space by the end of Q4 2026 [9][26] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant potential in the U.S. market [45] - Management noted that the new product launches are not included in the current revenue guidance of $180 million-$200 million for 2026 [28] Other Important Information - The company has $171.1 million in total adjusted liquid assets with $0 debt, providing ample runway for investment in IM8's global expansion [8] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][22] Question: Timing and characteristics of new product launches - Management confirmed plans to release two new SKUs in the health and performance space by the end of Q4 2026, targeting large total addressable markets [26] Question: Trends observed in January and revenue guidance - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [27][28] Question: Customer acquisition costs and lifetime values - Management provided insights on customer acquisition costs and lifetime values, indicating a payback period of approximately 3.4 months and a significant increase in average order value [33] Question: Use of AI in marketing - Management discussed leveraging AI for digital marketing, including ad optimization and content creation, resulting in significant engagement metrics [35][36] Question: Strategic M&A strategy - Management emphasized a focus on organic growth while remaining open to strategic M&A opportunities if they align with the company's goals [39]

Financial Data and Key Metrics Changes - Prenetics achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Q4 revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of revenue, generating $60.1 million for the full year 2025 at a gross margin of 63% [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue from IM8 at $27.4 million [4][9] - The average order value for new customers increased from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, while 60% came from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a revenue uplift of 10%-15% in local markets [46][47] Company Strategy and Development Direction - Prenetics completed a strategic pivot to focus solely on consumer health by divesting non-core assets, enhancing its margin profile and financial position [5][6] - The company aims to achieve adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][14] - Two new products are expected to launch by the end of Q4 2026, targeting large total addressable markets [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant opportunities in the US and international markets [44] Other Important Information - Prenetics has a total liquidity of approximately $171 million with zero debt, providing ample runway for investment in IM8's global expansion [7] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [7][8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management indicated that the quarterly subscription option was well-received by consumers, providing benefits for both sides, including upfront payment and reduced logistics costs [20][21] Question: Timing and characteristics of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements in large markets [25] Question: Trends observed in January and guidance for IM8 - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [26][27] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [32][33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, generating a high volume of ads and optimizing performance based on algorithmic feedback [34][35] Question: Strategic M&A strategy - The focus remains on organic growth, with openness to strategic M&A opportunities if they align with the company's goals [38] Question: Revenue growth sources and localization impact - Most growth is expected from new customer acquisition, with localization efforts anticipated to yield a 10%-15% revenue increase in targeted markets [44][46]